News

After a primary analysis revealed no significant differences in pain, exploratory outcomes in the FINAL trial also revealed no significant findings.

Dual-energy computed tomography results in faster dissolution of both the core and crown of tophi.

hsCRP may be a more accessible and reliable method of indicating inflammation, a known precursor to PsA.

Despite common practice avoiding benzbromarone, new data suggest it has a relatively low hepatotoxicity versus its more common counterpart in gout.

Our Q1 2025 recap for rheumatology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in rheumatology care.

Our top 5 headlines featured key FDA moves in nephrology and ophthalmology, from new approvals to trial terminations and priority reviews.

Regulatory approval of inebilizumab for immunoglobulin G4-related disease (IgG4-RD) marks the first and only available treatment for adults.

The rheumatology month in review emphasizes new research in gout, fibromyalgia, and psoriatic arthritis.

The rheumatology month in review emphasizes new research in gout, fibromyalgia, and psoriatic arthritis.

This FDA News Month in Review provides a round-up of regulatory decisions from March 2025.

By 3 months, nearly all patients confirmed exposed to 30 or 60 mg SAP-001 reached serum uric acid levels below 6mg/dL.

Small but significant decreases were also seen in depression and anxiety scores in people with and without psoriatic arthritis.

Hazard ratios of MACE were similar between patients treated with ustekinumab, adalimumab, etanercept, and secukinumab.

Other risk factors in the population included PZA or ETB use, hypertension, heart failure, and chronic kidney disease.

The two treatments appeared to be similar in cost-effectiveness and efficacy in a small analysis.

Analgesic effects lasted up to week 8 while function improvements lasted until week 16 in a new randomized, controlled trial.

MCP-1 and OPN combined had an AUC of 0.938 in diagnosing early renal injury.

Geraniol, linalool or α-humulene elevated mechanical thresholds in a time-dependent fashion in mice models of pain.

XORTX is meeting with the FDA in a Type B meeting regarding a potential NDA for XORLO.

Women, younger patients, and those with fibromyalgia were at particular risk of anxiety and depression, a new analysis shows.

A newly passed bill permits 2.8% Medicare physician payment cuts.

Data from the POETYK PsA-2 trial examining deucravacitinib were presented at the 2025 American Academy of Dermatology annual meeting.

The rheumatology month in review emphasizes new research in gout, fibromyalgia, and lupus.

The filing acceptance is based on positive data from the phase 3 REGENCY study. A decision on the approval is expected by October 2025.

The biosimilars are expected to become available in the US in June 2025.

The Phase 2b RENOIR trial met its primary endpoint and key secondary endpoints in patients with RA in new 12-week data.

Investigators hope that the model may serve as a foundation for future applications in gout diagnosis.

Copper had a positive association with FM risk and iron had a negative association.

Dual-energy computed tomography is able to characterize MSU in joints as well as chronic asymptomatic urolithiasis in kidneys.